Secondary prevention
Patients taking hormonal therapies should avoid prothrombogenic states such as obesity, smoking, or inactivity.
Hormone therapy may increase cardiovascular risk, particularly for trangender women taking feminising hormone therapy. For those with non-modifiable risk factors which may increase the risk of thromboembolic disease, for example, a known history of thrombophilia, a past history of thrombosis, or a strong family history of thromboembolism, offering an anticoagulant in addition to treatment with transdermal oestrogen may decrease the risk of thromboembolism, although data to guide treatment decisions are extremely limited.[4]
Note that traditional cardiovascular risk calculators do not take into account the use of current or past hormones. Factors to consider when estimating cardiovascular risk include the dose, length and age of onset of hormone therapy.[4] As a general guide, when estimating cardiovascular risk, it may be appropriate to use birth-assigned sex for those who have transitioned in later life, and to use a patient’s affirmed gender for those who have been taking hormone therapy since adolescence/young adulthood.[61]
Use of this content is subject to our disclaimer